The Biomedical Advanced Research and Development Authority (BARDA) is expanding a contract with Chrysalis BioTherapeutics, Inc. to pursue the development of TP508, or Chrysalin, a peptide with the potential to counteract injuries resulting from extreme radiation exposure. Radiation exposure can ... Read More » The post BARDA partnering with Chrysalis BioTherapeutics to create peptide capable of countering radiation appeared first on Homeland Preparedness News.
